Abstract
Glioblastoma is the most common primary malignant brain tumor diagnosed in the USA and is associated with a poor prognosis. The outcomes in elderly patients (more than 65 years of age) are worse when compared to those younger than age 65 at the time of diagnosis. Older patients are not always offered treatments that would otherwise be considered standard of care due to comorbidities and concerns about toxicity and tolerability. The initial European Organization for Research and Treatment of Cancer study that led to approval of temozolomide in glioblastoma excluded patients more than 70 years of age. This review outlines challenges that arise in the treatment of glioblastoma in the elderly population and discusses results of recent studies that established the role of adjuvant chemotherapy in addition to radiation and surgery. There is evidence that these patients can benefit from a more aggressive and safe resection, from hypofractionated radiation treatments, and from adjuvant temozolomide.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6). https://doi.org/10.1007/s00401-016-1545-1.
Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628–34. https://doi.org/10.1002/ana.21521.
Pallis AG, Ring A, Fortpied C, et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol. 2011;22(8):1922–6. https://doi.org/10.1093/annonc/mdq687.
Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-Oncology. 2014;16(11):1459–68. https://doi.org/10.1093/neuonc/nou063.
Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39–51. https://doi.org/10.1038/nrneurol.2009.197.
Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296–307. https://doi.org/10.1038/nrc1319.
Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005. https://doi.org/10.1056/NEJMoa043331.
Lalezari S, Chou AP, Tran A, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology. 2013;15(3):370–81. https://doi.org/10.1093/neuonc/nos308.
Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009;73(18):1509–10. https://doi.org/10.1212/WNL.0b013e3181bf9907.
Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neuro-Oncol. 2011;102(2):311–6. https://doi.org/10.1007/s11060-010-0324-4.
Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131(6):1342–50. https://doi.org/10.1002/ijc.27385.
Lu C, Ward P, Kapoor G, Rohle D. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–8. https://doi.org/10.1038/nature10860.IDH.
Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neuro-Oncol. 2012;108(1):11–27. https://doi.org/10.1007/s11060-011-0793-0.
Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology. 2013. https://doi.org/10.1093/neuonc/not043.
Yuan Y, Qi C, Maling G, et al. TERT mutation in glioma: frequency, prognosis and risk. J Clin Neurosci. 2016;26:57–62. https://doi.org/10.1016/j.jocn.2015.05.066.
Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–508. https://doi.org/10.1056/NEJMoa1407279.
Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma. JAMA Oncol. 2016;2(11):1460. https://doi.org/10.1001/jamaoncol.2016.1373.
Chaichana KL, Garzon-Muvdi T, Parker S, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18(1):239–45. https://doi.org/10.1245/s10434-010-1242-6.
Oszvald Á, Güresir E, Setzer M, et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg. 2012;116(2):357–64. https://doi.org/10.3171/2011.8.JNS102114.
• Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32(8):774–82. https://doi.org/10.1200/JCO.2013.51.8886. This analysis produced survival models for patients with glioblastoma of various ages and demonstrated relationships between survival and extent of resection, highlighting the importance of surgical resection in the treatment of these tumors.
• Noorbakhsh A, Tang JA, Marcus LP, et al. Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg. 2014;120(1):31–9. https://doi.org/10.3171/2013.9.JNS13877. This paper demonstrated that elderly patients with glioblastoma are less likely to receive a gross total resection in comparison with younger patients.
Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–35. https://doi.org/10.1056/NEJMoa065901.
Hottinger AF, Stupp R, Homicsko K. Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer. 2014;33(1):32–9. https://doi.org/10.5732/cjc.013.10207.
Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, GRegory Cairncross J. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol. 1994;29(4):835–9. https://doi.org/10.1016/0360-3016(94)90573-8.
• Arvold ND, Tanguturi SK, Aizer AA, et al. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol. 2015;92(2):384–9. https://doi.org/10.1016/j.ijrobp.2015.01.017. This study demonstrated that when controlling for the selection bias against patients with a lower performance status, there were no overall survival differences between SRT and HRT when given with concurrent TMZ in elderly patients.
Roa W, Kepka L, Kumar N, et al. International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33(35):4145–50. https://doi.org/10.1200/JCO.2015.62.6606.
Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583–8. https://doi.org/10.1200/JCO.2004.06.082.
Chamberlain MC, Recht LD, Glantz M. Regarding “abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial”. J Clin Oncol. 2005;23(7):1587–8. https://doi.org/10.1200/JCO.2005.05.292.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi.org/10.1056/NEJMoa043330.
Alliot C. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Cancer. 2004;101(12):2897–8. https://doi.org/10.1002/cncr.20707.
Gállego Pérez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29(22):3050–5. https://doi.org/10.1200/JCO.2011.34.8086.
• Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR. Glioblastoma care in the elderly. Cancer. 2016;122(2):189–97. https://doi.org/10.1002/cncr.29742. This is a comprehensive review of published evidence regarding glioblastoma care in the elderly.
Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer. 2003;97(9):2262–6. https://doi.org/10.1002/cncr.11323.
Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2013;39(4):350–7. https://doi.org/10.1016/j.ctrv.2012.05.008.
•• Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–37. https://doi.org/10.1056/NEJMoa1611977. This study demonstrated that the addition of temozolomide to short-course radiotherapy prolongs survival in elderly patients with glioblastoma without sacrifice in quality of life.
Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26. https://doi.org/10.1016/S1470-2045(12)70265-6.
Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–15. https://doi.org/10.1016/S1470-2045(12)70164-X.
Amsbaugh MJ, Yusuf MB, Gaskins J, Burton EC, Woo SY. Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: an analysis of the National Cancer Database. https://doi.org/10.1002/cncr.30730.
Perazzoli G, Prados J, Ortiz R, et al. Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression. Alonso MM, ed PLoS One 2015;10(10):e0140131. https://doi.org/10.1371/journal.pone.0140131.
Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–5. https://doi.org/10.1200/JCO.2008.16.3055.
Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217–22. https://doi.org/10.1212/01.wnl.0000345668.03039.90.
Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29(2):142–8. https://doi.org/10.1200/JCO.2010.30.2729.
• Mason M, Laperriere N, Wick W, et al. Glioblastoma in the elderly: making sense of the evidence. Neuro-Oncology Pract. 2016;3(2):77–86. https://doi.org/10.1093/nop/npv027. This is a systematic review of evidence regarding glioblastoma care in the elderly that discusses the role of bevacizumab.
Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17(12). http://clincancerres.aacrjournals.org/content/17/12/4119.short. Accessed April 27, 2017
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–22. https://doi.org/10.1056/NEJMoa1308345. This study assesses the use of bevacizumab in addition to first-line treatment in glioblastoma.
Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. https://doi.org/10.1056/NEJMoa1308573.
Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade glioma. In: Khasraw M, editor. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 2014. https://doi.org/10.1002/14651858.CD008218.pub3.
Santoni M, Scoccianti S, Lolli I, et al. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. J Neuro-Oncol. 2013;113(3):397–401. https://doi.org/10.1007/s11060-013-1125-3.
Boele FW, Douw L, de Groot M, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro-Oncology. 2013;15(10):1420–8. https://doi.org/10.1093/neuonc/not102.
Gehring K, Patwardhan SY, Collins R, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neuro-Oncol. 2012;107(1):165–74. https://doi.org/10.1007/s11060-011-0723-1.
Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin. 2007;25(4):1035–71. https://doi.org/10.1016/j.ncl.2007.07.015.
Funding
The work of MSA was supported by the Dean and Diane Miller Family Chair in Neuro-Oncology.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Kelly Braun declares that she has no conflict of interest. Manmeet S. Ahluwalia has received research support through grants from Monteris Medical, AbbVie, Bristol-Myers Squibb, AstraZeneca, Novocure, Novartis, Incyte, Pharmacyclics, and TRACON Pharmaceuticals, and has received compensation from Monteris Medical, AbbVie, Bristol-Myers Squibb, AstraZeneca, Datar Genetics Ltd., CBT Pharmaceuticals, Kadmon Pharmaceuticals, Elsevier, Novocure, Incyte, prIME Oncology, and Caris Life Sciences for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Geriatric Oncology
Rights and permissions
About this article
Cite this article
Braun, K., Ahluwalia, M.S. Treatment of Glioblastoma in Older Adults. Curr Oncol Rep 19, 81 (2017). https://doi.org/10.1007/s11912-017-0644-z
Published:
DOI: https://doi.org/10.1007/s11912-017-0644-z